# Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas

> **NCT02304458** · PHASE1,PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 140 (actual)

## Conditions studied

- Metastatic Melanoma
- Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
- Recurrent Hodgkin Lymphoma
- Recurrent Malignant Solid Neoplasm
- Recurrent Melanoma
- Recurrent Neuroblastoma
- Recurrent Non-Hodgkin Lymphoma
- Recurrent Osteosarcoma
- Recurrent Rhabdomyosarcoma
- Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
- Refractory Hodgkin Lymphoma
- Refractory Malignant Solid Neoplasm
- Refractory Melanoma
- Refractory Neuroblastoma
- Refractory Non-Hodgkin Lymphoma
- Refractory Osteosarcoma
- Refractory Rhabdomyosarcoma
- Stage III Cutaneous Melanoma AJCC v7
- Stage IIIA Cutaneous Melanoma AJCC v7
- Stage IIIB Cutaneous Melanoma AJCC v7
- Stage IIIC Cutaneous Melanoma AJCC v7
- Stage IV Cutaneous Melanoma AJCC v6 and v7
- Unresectable Melanoma

## Interventions

- **BIOLOGICAL:** Ipilimumab
- **OTHER:** Laboratory Biomarker Analysis
- **BIOLOGICAL:** Nivolumab
- **OTHER:** Pharmacological Study

## Key facts

- **NCT ID:** NCT02304458
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03-30
- **Primary completion:** 2021-09-30
- **Final completion:** 2023-03-31
- **Target enrollment:** 140 (ACTUAL)
- **Last updated:** 2023-10-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02304458

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02304458, "Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02304458. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*